Clinical Trials Logo

Mild Cognitive Impairment clinical trials

View clinical trials related to Mild Cognitive Impairment.

Filter by:

NCT ID: NCT05514106 Enrolling by invitation - Dementia Clinical Trials

MIBG in Aging and Neurologic Disorders

Start date: May 8, 2023
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate the use of a special radioactive drug called 123I-MIBG and myocardial MIBG scintigraphy. This scan may be able to help determine who may have a certain kind of neurologic disorder called Lewy Body Disease. The overall purpose of this study is to correlate myocardial MIBG scintigraphy findings with clinical diagnosis. Myocardial MIBG scintigraphy imaging will be combined with other clinical, neuropsychological and neuroimaging findings to improve the prediction for underlying Lewy Body Disease.

NCT ID: NCT05448768 Enrolling by invitation - Clinical trials for Mild Cognitive Impairment

Cognitive Effects and Potential Mechanisms of TBS in Subjects With MCI

Start date: September 13, 2022
Phase: N/A
Study type: Interventional

This study aims to examine the effects and potential mechanisms of theta-burst stimulation (TBS) on cognitive function in individuals with mild cognitive impairment (MCI).

NCT ID: NCT05433883 Enrolling by invitation - Clinical trials for Mild Cognitive Impairment

The Relationship Between Obstructive Sleep Apnea and Alzheimer's Disease: Evidence and Effectiveness

OSA
Start date: November 3, 2020
Phase: N/A
Study type: Interventional

The research plan to enroll 15 simple snoring patients (apnea/hypopnea <5, control group), 30 severe OSA patients (apnea/hypopnea >30, treatment group), and 15 mild cognitive impairment patients (comparative group). All patients complete Mini-Mental State Examination, peripheral blood sample for plasma Aβ42, Aβ40, Aβ42/Aβ40, Tau, NfL; amyloid deposit in18F-florbetapir PET; and Taiwan smell identification test. Thirty severe OSA patients (AHI>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.

NCT ID: NCT05216315 Enrolling by invitation - Alzheimer Disease Clinical Trials

tDCS and Cognitive Efficiency

FRtDCS
Start date: July 30, 2020
Phase: N/A
Study type: Interventional

Normal aging is associated with a progressive decline in cognitive functions, especially memory. This decline in cognitive function can negatively impact the quality of life of older adults. Although there are currently few possibilities to prevent and/or slow the signs of cognitive decline, both those associated with age and neurodegenerative pathologies, one of the non-invasive brain stimulation techniques that has gained attention in recent years is Transcranial Direct Current Stimulation (tDCS). tDCS is a technique based on the application of a low-intensity (< 2 mA) direct electrical current between two large-area electrodes placed on various surface areas of the head. Moreover, according to safety-related meta-analyses it is a very safe technique, without any major side effects, provided that internationally established safety protocols are taken into account in its application. This technique has recently been investigated as a potential treatment for both healthy elderly people and people with mild cognitive impairment and Alzheimer's disease in several cognitive variables, having shown encouraging results in working memory learning curves, modulation of plasticity and recognition tasks. This project aims to implement an intervention using transcranial direct current stimulation in healthy older adults, MCI and AD. The main objective is to test if there is an improvement in cognitive efficiency and if the changes are maintained over time (1 month). For this purpose, the effect of the technique will be studied on participants assigned to treatment and control groups, analyzing the possible modifications in the following cognitive variables: cognitive plasticity and learning potential, recognition and familiarity and false alarms.

NCT ID: NCT05028920 Enrolling by invitation - Clinical trials for Mild Cognitive Impairment

The Study on Nutritional Status of Patients With Mild Cognitive Impairment

Start date: July 1, 2021
Phase:
Study type: Observational

The global aging population is rising year by year. According to the result of Taiwan epidemiological survey, dementia has become the health issue in aging population. Mild cognitive function impairment may present years before dementia is diagnosed. Therefore early diagnosis of dementia at its Mild cognitive function impairment stage is beneficial for disease prevention and potentially delaying the deterioration of cognitive function impairment. Nutritional status includes a healthy diet, favor body composition and activity habits, which not only reduces the risk of nutritional metabolic diseases, but also has a direct relationship with delaying cognitive function impairment. The dietary quality index of Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay diet (MIND diet) may prevent aging and positively associated with delaying dementia in elderly. However, the result in dietary quality index and delaying cognitive function impairment from current studies were still unclear. In additions, based on the differences in dietary patterns between Taiwan and Western countries, no current calorie and dietary nutrition recommendations. This cross-sectional study is to investigate the association between dietary quality index and nutritional status risk factors in cognitive function impairment patients and expected to develop an assessment tool for Taiwanese clinical nutrition strategies and applications.

NCT ID: NCT04954183 Enrolling by invitation - Alzheimer Disease Clinical Trials

Development of an EEG Diagnostic for Alzheimer's Disease

Start date: October 1, 2021
Phase:
Study type: Observational

The purpose of this research is to collect and compare electroencephalogram data from all stages of Alzheimer's disease from preclinical through severe dementia.

NCT ID: NCT04818255 Enrolling by invitation - Clinical trials for Mild Cognitive Impairment

STIM+: PET Biomarker Education & Disclosure

STIM+
Start date: December 10, 2020
Phase: N/A
Study type: Interventional

When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging. Studies have shown that changes in the brain happen before full symptoms of DAT develop. These changes include a buildup of two proteins within the brain, called amyloid and tau. The two goals of this study are (1) to determine whether patients with mild cognitive impairment or dementia-Alzheimer's type (DAT) are able to demonstrate decisional capacity to engage in PET amyloid and tau disclosure after receiving education; and (2) to assess how patients and care partners react to PET amyloid and tau biomarker disclosure.

NCT ID: NCT04785300 Enrolling by invitation - Alzheimer Disease Clinical Trials

ALSENLITE: Senolytics for Alzheimer's Disease

Start date: July 6, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being done to evaluate the safety and feasibility of using Dasatinib and Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.

NCT ID: NCT04701177 Enrolling by invitation - Alzheimer Disease Clinical Trials

Digitally-enhanced, Decentralized, Multi-omics Observational Cohort

ANANEOS
Start date: March 15, 2021
Phase:
Study type: Observational [Patient Registry]

The study is carried out as part of the GR2021 Priority project "Healthy Brains for life (Age 20-99): Digitally-enhanced personalized medicine study ANANEOS" and code numbered GR-00546 and it will look at the decentralized and remote assessment of the symptoms of preclinical stages in Alzheimer's disease and movement disorders, e.g. Parkinson's. For this study we are looking for participants aged over 45 without cognitive complaints or with subjective perception of cognitive decline or with mild cognitive complaints. Specific aims for the proposed study: a) to develop novel sensitive measures that can provide an early identification of those SCD and MCI individuals harboring AD pathology that are at high risk of cognitive worsening over time; b) to track pre-motor stages in Parkinson's disease and trials that enable active digital functional biomarkers; c) to track disease progression during pre-dementia and pre-motor stages in clinical practice and trials with measures that enable to capture subtle changes.

NCT ID: NCT04482660 Enrolling by invitation - Healthy Clinical Trials

Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population

Start date: March 29, 2021
Phase: N/A
Study type: Interventional

This study will characterize tau tracer retention by Positron Emission Tomography (PET) as a function of amyloid levels transversally and longitudinally.